Bayer's third-quarter sales came in a bit higher than anticipated, but the company is girding its loins for a challenging period ahead as generic competition and litigation liabilities bed in. Pharma ...

At ESMO 2025 in Berlin, pharmaphorum spoke with Tadaaki Taniguchi, Chief Research & Development Officer at Astellas, about ...

On World Diabetes Day, Sanofi is celebrating an approval recommendation in the EU for Teizeild, a first-in-class drug ...

In a statement, Avadel acknowledged that it had received the Lundbeck bid and that its board of directors had "determined in ...

MSD has announced a takeover deal for Cidara Therapeutics, an infectious disease specialist currently focused on developing a ...

This World Diabetes Day, Sanofi UK and DigiBete are hosting a pop-up event in Leeds today and tomorrow, 14th & 15th November, ...

Kura Oncology has claimed FDA approval for oral menin inhibitor Komzifti for a form of acute myeloid leukaemia (AML), making ...

Anglo-Swiss life sciences investment company Medicxi has raised €500 million (around $579 million) for its sixth fund, which will focus on supporting 'asset-centric' companies at all stages of drug ...

A phase 2 trial of enGene's detalimogene voraplasmid in non-muscle invasive bladder cancer (NMIBC) has delivered a positive result, setting it on course for a filing with the FDA next year. The LEGEND ...

Reimbursement authority NICE published draft guidance today giving a green light to the use of Columvi (glofitamab) in ...

The alliance between AbbVie and Calico dates back to 2014, just a year after it was launched by Alphabet's Google unit, when ...